ChemInform Abstract: Stereoselective Synthesis of Melatonin Receptor Agonist Ramelteon via Asymmetric Michael Addition.

ChemInform ◽  
2012 ◽  
Vol 43 (21) ◽  
pp. no-no
Author(s):  
Xuan Zhang ◽  
Wei Yuan ◽  
Yu Luo ◽  
Qing-Qing Huang ◽  
Wei Lu
Keyword(s):  
Michael Addition ◽  
Receptor Agonist ◽  
Stereoselective Synthesis ◽  
Melatonin Receptor ◽  
Asymmetric Michael Addition

Stereoselective Synthesis of Melatonin Receptor Agonist Ramelteon via Asymmetric Michael Addition

Heterocycles ◽  
2012 ◽  
Vol 85 (1) ◽  
pp. 73 ◽  
Author(s):  
Wei Lu ◽  
Wei Yuan ◽  
Yu Luo ◽  
Qing-Qing Huang ◽  
Xuan Zhang
Keyword(s):  
Michael Addition ◽  
Receptor Agonist ◽  
Stereoselective Synthesis ◽  
Melatonin Receptor ◽  
Asymmetric Michael Addition

Approach to the stereoselective synthesis of melatonin receptor agonist Ramelteon via asymmetric hydrogenation

2006 ◽  
Vol 17 (2) ◽  
pp. 184-190 ◽  
Author(s):  
Toru Yamano ◽  
Masayuki Yamashita ◽  
Mari Adachi ◽  
Mitsutaka Tanaka ◽  
Kiyoharu Matsumoto ◽  
...  
Keyword(s):  
Receptor Agonist ◽  
Stereoselective Synthesis ◽  
Asymmetric Hydrogenation ◽  
Melatonin Receptor

Effect of melatonin receptor agonist Neu-P11 on phosphorylation of protein kinase B in mouse 3T3-L1 adipocytes

2015 ◽  
Vol 36 (7) ◽  
pp. 802
Author(s):  
Xiu-ping LI ◽  
Shi-chang CAI ◽  
Wei-dong YIN ◽  
Su-jun ZHANG ◽  
Rong HU ◽  
...  
Keyword(s):  
Protein Kinase ◽  
Receptor Agonist ◽  
Protein Kinase B ◽  
Melatonin Receptor

Evaluation of Delirium in Critically Ill Patients Prescribed Melatonin or Ramelteon

2021 ◽  
pp. 106002802110020
Author(s):  
Natasha Romero ◽  
Kevin M. Dube ◽  
Kenneth E. Lupi ◽  
Jeremy R. DeGrado
Keyword(s):  
Clinical Outcomes ◽  
Critically Ill ◽  
Critically Ill Patients ◽  
Receptor Agonist ◽  
Hospital Length ◽  
Hospital Length Of Stay ◽  
Melatonin Receptor ◽  
Observational Cohort ◽  
Impaired Sleep ◽  
Retrospective Observational Cohort Study

Background: An impaired sleep-wake cycle may be one factor that affects the development of delirium in critically ill patients. Several small studies suggest that exogenous melatonin or ramelteon may decrease the incidence and/or duration of delirium. Objective: To compare the effect of prophylactic administration of melatonin, ramelteon, or no melatonin receptor agonist on the development of delirium in the intensive care unit (ICU). Methods: This was a single-center, retrospective, observational cohort study of nondelirious patients in the ICU who received melatonin, ramelteon, or no melatonin receptor agonist. The primary end point was the incidence of delirium. Secondary end points included assessments of daily level of sedation and daily utilization of antipsychotic, sedative, and opioid agents. Results: No difference was observed in the incidence of delirium among the melatonin, ramelteon, and placebo cohorts (18.7% vs 14.3% vs 13.8%; P = 0.77). A difference was observed in the rate of agitation and sedation among the 3 groups, with the greatest observed in the melatonin cohort. Additionally, there was a difference in the use of propofol, dexmedetomidine, and opioids. Overall, there was no difference in clinical outcomes, including duration of mechanical ventilation and ICU or hospital length of stay. Conclusion and Relevance: Therapy with melatonin, ramelteon, and no melatonin receptor agonist resulted in similar rates of delirium in a mixed ICU population. Despite significant differences in agitation, sedation, and medication utilization, there was no differences in the clinical outcomes evaluated.

Pyrrolidinyl-Camphor Derivatives as a New Class of Organocatalyst for Direct Asymmetric Michael Addition of Aldehydes and Ketones to β-Nitroalkenes

2010 ◽  
Vol 16 (23) ◽  
pp. 7030-7038 ◽  
Author(s):  
Ying-Fang Ting ◽  
Chihliang Chang ◽  
Raju Jannapu Reddy ◽  
Dhananjay R. Magar ◽  
Kwunmin Chen
Keyword(s):  
Michael Addition ◽  
New Class ◽  
Asymmetric Michael Addition ◽  
Aldehydes And Ketones ◽  
Camphor Derivatives
Sign in / Sign up

Export Citation Format

Share Document